Medicine and Health Sciences Commons^™

Lncrna Impact On Regorafenib Resistance In Colorectal Cancer, Ricardo Pequeno Bracho, Kyle Doxtater, Dennis Kwabiah, Yamile Abuchard Anaya, Sophia Leslie, Mohammad Shabir Hussain, Manish Tripathi

Research Symposium

Cancer metastasis is one of the deadliest aspects of the disease, with about 90% of all cancer-related deaths due to its development at different sites within the body. Colorectal cancer (CRC) is the second leading cause of cancer mortality in the United States, with 40-50% of all patients developing metastasis at some point during their fight with the disease. With the approval of Regorafenib for treating metastatic colorectal cancer, steps have been taken to combat metastasis in colorectal cancer. A vital aspect of the development of metastasis is the development of resistance to first-line chemotherapy. Regorafenib is an oral small-molecule …

Targeted Treatment For Kras12d For Pdac Treatment, Ana Bulnes, Orlando Garcia, Poornima Devi Shaji, Melissa Elizondo, Swathi Holla, Nirnoy Dan, Anupam Dhasmana, Shabnam Malik, Murali Yallapu, Stephen Behrman

Research Symposium

Introduction: Cellular stress is known to function in synergistic cooperation with oncogenic mutations during tumorigenesis to drive cancer progression. Oncogenic RAS is a strong inducer of a variety of pro-tumorigenic cellular stresses, and also enhances the ability of cells to tolerate these stresses through multiple mechanisms that leads to resistance to chemotherapy and to therapies that target the RAS pathway. Pancreatic Ductal Adenocarcinoma (PDAC) patients exhibit extremely poor prognosis. KRAS mutation on codon-12 is present in 70–95% of PDAC cases and it drives stress-adaptive mechanisms, PDAC growth and progression. Galectin-1 (Gal-1) is present in both PDAC and stromal cells, being …

Studying The Molecular Mechanism Of Hepatocellular Carcinoma, Shabnam Malik, Mohammed Sikander, S. Mishra, Daniel Zubieta, S. K. Jain, Deepshikha Pande Katare, Meena Jaggi, Subhash Chauhan

Research Symposium

Background: Hepatocellular carcinoma (HCC) has a poor prognosis due to ineffective therapeutic modality and lack of early diagnostic marker. Accumulating studies have shown that elevated expression of mucin 13 as potential oncogene and predictive biomarker for various cancer. However, very little is known about its expression and function for development and progression of HCC.

Objective: To investigate mucin 13 expression in chemically induced hepatocellular carcinoma model.

Methodology: Diethyl nitrosamine (DEN) and 2-Acetylaminofluorene (2-AAF) induced method was employed for the development of hepatocellular carcinoma in Male Wistar rats. Serum and tissues were collected at regular intervals of time and routinely validated …